The Moldovan government intends to lift restrictions on opening new pharmacies and change the pricing mechanism for certain medications. These measures are included in a business deregulation package approved on November 18. However, the reform affects a market where pharmacies are unevenly distributed, the range of medications is shrinking, and imports account for the overwhelming majority of sales. At the same time, the government is lifting restrictions on the expansion of pharmacy chains and subsidizing their operations in rural areas. To what extent will the new rules improve the situation for consumers, rather than just the operating conditions for the pharmaceutical industry?
Currently, the location of pharmacies in Moldova is regulated by a minimum distance of 250 meters between them and a standard of one pharmacy per 3,000–4,000 residents in cities. The government proposes to repeal both requirements. If Parliament passes the bill, business owners will be able to choose locations for new pharmacies based on commercial viability.
According to calculations provided in the explanatory note to the bill, the existing restrictions, related legal proceedings, and associated delays result in costs of approximately 772,000 lei per pharmacy. Their repeal should make it easier for new entrants to enter the market and for existing chains to expand.
Moldova's problem lies not so much in the total number of pharmacies as in their uneven distribution. According to 2023 data from the Ministry of Health, there were 101 pharmacies per 100,000 urban residents, compared to just 39 in rural areas—a 2.6-fold difference. At the same time, according to the ministry's estimates, the overall density of the pharmacy network in Moldova exceeds the average for countries in the Organization for Economic Cooperation and Development (OECD).
The pharmacy network continues to expand. According to the Agency for Medicines and Medical Devices, there were 1,800 pharmacies in Moldova in 2025, compared to 1,697 the previous year. The number of pharmacies in rural areas increased from 606 to 719. However, this growth is also driven by government support.
The "A Pharmacy in Your Village" program has been in effect since March 2024. By July 2026, 135 subsidized pharmacies had opened under this program, serving approximately 180,000 residents. The government provides entrepreneurs with 10,000 to 20,000 lei per month to compensate for the lack of commercial viability of operating in small communities.
But even financial support does not guarantee that pharmacies will open. Of the 225 villages included in the competitive bidding process, the winners in 44 of them subsequently declined to carry out their projects. In some villages, the monthly revenue of pharmacies turned out to be lower than the minimum government subsidy. Herewith, the program is aimed at villages with a population of more than 1,000 people.
This creates an economic contradiction: in cities, the government intends to remove restrictions that hinder the further expansion of pharmacy chains, while in villages it is forced to fund their presence out of the budget. This highlights the limitations of market mechanisms, although it does not in itself constitute an argument for maintaining territorial restrictions.
An even more sensitive aspect of the reform concerns pricing. The bill provides for a simplified approval process for manufacturers' wholesale prices for certain over-the-counter drugs that do not fall into protected categories. This does not involve the complete abolition of state control, but rather a change in the mechanism for determining the base price of drugs.
The Agency for Medicines and Medical Devices (AMDM) will continue to maintain a catalog of manufacturers' prices. For the relevant over-the-counter drugs, it is proposed that prices be approved based on a notification from the manufacturer or the marketing authorization holder. These prices will be included in the catalog and used to calculate maximum retail markups, the limits on which will remain in place.
The Ministry of Health had previously warned of the risks of hasty liberalization. The ministry proposed first revising the mechanism for setting manufacturers' prices, then enacting a new law on pharmacies, and only then changing the regulation of wholesale and retail prices. Until the transition period ends, the current control mechanisms should remain in place. The package approved by the government provides for a more direct change to the pricing procedure. It is not yet clear to what extent these approaches are aligned.
According to the Ministry of Health's estimates, the proposed set of changes to pharmaceutical regulation could generate savings of up to 375 million lei annually for the public and the health insurance system. However, this forecast from the ministry refers to a broader reform, not just the deregulation package approved by the government on November 18.
For consumers, it is crucial to understand that the final cost of a medication depends not only on the manufacturer's price. It is also influenced by import conditions, markups, taxes, and the number of suppliers. Even with a well-developed pharmacy network, choice remains limited if cheaper alternatives are not available on the market.
According to the Agency for Medicines and Medical Devices, in 2025, imported drugs accounted for about 92.9% of the value of Moldova's pharmaceutical market. Therefore, local pharmacies have limited ability to influence the base price of a significant portion of their product range.
According to the Ministry of Health, drug sales in pharmacies rose from approximately 4.32 billion lei in 2021 to 5.4 billion lei in 2025, or by 1.08 billion lei (+25%), with the number of packages sold remaining roughly unchanged. Meanwhile, prices for over-the-counter medications increased by 12.5%, although the number of packages purchased decreased by 9%.
At the same time, the product range is shrinking. According to the Ministry of Health, 1,553 drug items disappeared from the market between 2021 and 2025, while 845 new ones appeared. The net reduction amounted to 708 items. Inexpensive drugs proved to be particularly vulnerable: 574 items disappeared from the category of drugs with a manufacturer's selling price of up to 30 lei, while only 155 new ones appeared.
Drug registration in Moldova does not guarantee its actual availability in pharmacies. A manufacturer or importer may refuse to supply a drug if economic conditions make it unprofitable to do so. Changing the pricing mechanism could create incentives for certain drugs to return to the market, but the outcome will depend on the decisions of suppliers.
The deregulation package also includes other measures to reduce costs for the pharmaceutical industry. In particular, according to government estimates, the elimination of certain permits for importing raw materials used in the production of registered drugs could yield savings of more than 10 million lei annually. However, a reduction in administrative costs will not necessarily be reflected in the final price of drugs. The savings could increase companies' profits rather than lead to lower prices for consumers.
Thus, the reform has the potential to streamline operations in the pharmaceutical industry, but its impact on consumers remains unclear. The main risk is that the government will remove administrative barriers, while the main problems faced by consumers—high prices and a shrinking selection of affordable medications—will persist. What matters is not how many licenses will be revoked or how many new pharmacies will open, but whether patients' out-of-pocket costs will decrease and whether necessary medications will be available for purchase. // 21.11.2026 – InfoMarket.